Objective: To examine the treatment patterns of onabotulinumtoxinA utilization in patients treated for upper and lower limb spasticity, in combination, from the ASPIRE study (1 year interim results).

Background: OnabotulinumtoxinA treatment for patients with spasticity is individualized, variable, and dependent on numerous factors.

Methods: This is an international, prospective, multicenter, observational registry conducted at select North America, Europe, and Asia sites (NCT01930786) examining adults with spasticity. Patients were administered onabotulinumtoxinA with treatment dosing at intervals at the treating physician’s discretion. Utilization patterns were assessed at each treatment visit.

Results: A total of 256 patients were treated for both upper and lower limb spasticity across 648 treatment sessions at the 1 year interim data cut. The average total dose administered to the upper and lower limbs was 468 U (SD=186) across the 648 treatment sessions. The majority of treatment sessions occurred at a dosing interval of 10-15 weeks (n=236/392, 60.2%) or >15 weeks (n=153/392, 39.0%). Muscles in the upper and lower limbs received a total of 5-15 injections at 62.3% of treatment sessions (n=404/648) and >15 injections at 36.3% of treatment sessions (n=235/648). Greater than 5 upper and lower limb muscles were injected during the majority of treatment sessions (n=530/648, 81.8%). No new safety concerns were identified for the total population at the 1 year interim analyses.

Conclusions: The one year interim results of our study provide insight into the real-world treatment patterns of onabotulinumtoxinA in adult patients treated concurrently for both upper and lower limb spasticity and offers valuable guidance to clinicians.

« Back to 2017 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/the-adult-spasticity-international-registry-aspire-study-treatment-utilization-patterns-in-patients-treated-for-both-upper-and-lower-limb-spasticity/